DIPG-72. CREATION, CHARACTERIZATION AND CATALOGUING NEXT-GENERATION DIPG PATIENT-DERIVED CANCER CELL LINES: THE DIPG C3 PROJECT

Sonam Bhatia(Dana-Farber Cancer Institute), Katherine Warren(Dana-Farber Cancer Institute), Keith L. Ligon(Brigham and Women's Hospital), Smitha Yerrum(Dana-Farber Cancer Institute), Thomas C. Quinn(Johns Hopkins University), Michelle Monje(Howard Hughes Medical Institute), Kin-Hoe Chow(Dana-Farber Cancer Institute), Eric H. Raabe(Johns Hopkins University), Jayne Vogelzang(Dana-Farber Cancer Institute), Mariella G. Filbin(Broad Institute), Esther Hulleman(Amsterdam UMC Location VUmc), Aniket Shetty(Dana-Farber Cancer Institute)
Neuro-Oncology
June 18, 2024
10.1093/neuonc/noae064.125
Cited by 1

Related Papers

Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
|Science|1997|3.1k
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
|Nature|2022|769
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711
Distinguishing features of long COVID identified through immune profiling
|Nature|2023|676
Epidermal growth factor receptor and Ink4a/Arf
|Cancer Cell|2002|647